Investigational drug · Phase 2
BLEX 404
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "BLEX 404"
First trial start
2026
Jul 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BLEX 404", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Nonsquamous Nonsmall Cell Neoplasm of Lung
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BLEX 404" as an intervention, largest first.
BioLite, Inc.Industry
NCT02944955 · 52 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2028
Drug: BLEX 404 Oral Liquid · For: Myelodysplastic Syndrome (MDS)
- Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.Not yet recruiting
BioLite, Inc.Industry
NCT02802423 · 44 participants (planned) · Start Jan 1, 2027 · Primary completion Apr 30, 2028
Drug: BLEX 404 Oral Liquid · For: Triple Negative Breast Cancer
- A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic CancerNot yet recruiting
Rgene CorporationIndustry
NCT03301805 · 40 participants (planned) · Start Jul 1, 2026 · Primary completion Apr 30, 2027
Drug: BLEX 404 · For: Pancreatic Cancer
- Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin TherapyNot yet recruiting
Rgene CorporationIndustry
NCT05764928 · 32 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: BLEX 404 · For: Nonsquamous Nonsmall Cell Neoplasm of Lung
Sites: Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.